Modelling and Simulation in the Development and use of Anti-Cancer Agents: An Underused Tool?
暂无分享,去创建一个
France Mentré | Leon Aarons | Amy Racine | Jean-Louis Steimer | Peter Nygren | Mats Karlsson | L. Aarons | J. Steimer | A. Racine | M. Karlsson | I. Trocóniz | P. Nygren | F. Mentré | A. van Peer | Ferdinand Rombout | Anthony Man | Hans Schaefer | Iñaki Troconiz | Achiel van Peer | invited COST B15 Experts | H. Schaefer | F. Rombout | Anthony Man | invited Cost B15 Experts
[1] H. Harashima,et al. Development of a pharmacokinetic/pharmacodynamic (PK/PD)-simulation system for doxorubicin in long circulating liposomes in mice using peritoneal P388. , 1999, Journal of controlled release : official journal of the Controlled Release Society.
[2] P Bauer,et al. Interim Analysis and Sample Size Reassessment , 2000, Biometrics.
[3] H. H. Lloyd,et al. Adequacies and inadequacies in assessing murine toxicity data with antineoplastic agents. , 1979, Cancer research.
[4] R. Simon,et al. Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.
[5] J. Wingard,et al. Association of busulfan area under the curve with veno-occlusive disease following BMT. , 1996, Bone marrow transplantation.
[6] R Simon,et al. Accelerated titration designs for phase I clinical trials in oncology. , 1997, Journal of the National Cancer Institute.
[7] J O'Quigley,et al. Continual reassessment method: a likelihood approach. , 1996, Biometrics.
[8] M R Conaway,et al. Designs for phase II trials allowing for a trade-off between response and toxicity. , 1996, Biometrics.
[9] M. Relling,et al. Mercaptopurine therapy intolerance and heterozygosity at the thiopurine S-methyltransferase gene locus. , 1999, Journal of the National Cancer Institute.
[10] D. Newell,et al. Revisions of general guidelines for the preclinical toxicology of new cytotoxic anticancer agents in Europe. The Cancer Research Campaign (CRC) Phase I/II Clinical Trials Committee and the European Organization for Research and Treatment of Cancer (EORTC) New Drug Development Office. , 1995, European journal of cancer.
[11] R. Jain,et al. Delivery of molecular and cellular medicine to solid tumors. , 1998, Journal of controlled release : official journal of the Controlled Release Society.
[12] M Buyse,et al. On the relationship between response to treatment and survival time. , 1996, Statistics in medicine.
[13] Mats O Karlsson,et al. Model of chemotherapy-induced myelosuppression with parameter consistency across drugs. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[14] R. Gelber,et al. A quality-adjusted time without symptoms or toxicity (Q-TWiST) analysis of adjuvant radiation therapy and chemotherapy for resectable rectal cancer. , 1996, Journal of the National Cancer Institute.
[15] L. Weisenthal. Antineoplastic drug screening belongs in the laboratory, not in the clinic. , 1992, Journal of the National Cancer Institute.
[16] S. Nandi,et al. Beware of contaminating mouse cells in human xenografts from nude mice. , 2000, Anticancer research.
[17] N Stallard,et al. Sample size determination for phase II clinical trials based on Bayesian decision theory. , 1998, Biometrics.
[18] N H Holford,et al. Simulation of clinical trials. , 2000, Annual review of pharmacology and toxicology.
[19] B. Druker,et al. STI571: a paradigm of new agents for cancer therapeutics. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] L B Sheiner,et al. Population pharmacokinetics/pharmacodynamics of docetaxel in phase II studies in patients with cancer. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] S Chevret,et al. The continual reassessment method in cancer phase I clinical trials: a simulation study. , 1993, Statistics in medicine.
[22] T. Fleming,et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. , 2001, The New England journal of medicine.
[23] Roy S Herbst,et al. Mode of action of docetaxel - a basis for combination with novel anticancer agents. , 2003, Cancer treatment reviews.
[24] J. Herndon,et al. A design alternative for two-stage, phase II, multicenter cancer clinical trials. , 1998, Controlled clinical trials.
[25] R. Kerbel. What is the Optimal Rodent Model for Anti-tumor Drug Testing? , 1998, Cancer and Metastasis Reviews.
[26] I. Fidler,et al. Critical determinants of cancer metastasis: rationale for therapy , 1999, Cancer Chemotherapy and Pharmacology.
[27] R. Gelber,et al. Quality-of-life-adjusted survival analysis of interferon alfa-2b adjuvant treatment of high-risk resected cutaneous melanoma: an Eastern Cooperative Oncology Group study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[28] B. Fingleton,et al. Matrix metalloproteinases: biologic activity and clinical implications. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[29] M. Buyse,et al. What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? , 1993 .
[30] John O'Quigley,et al. Continual reassessment designs with early termination. , 2002, Biostatistics.
[31] G Molenberghs,et al. Sensitivity Analysis for Nonrandom Dropout: A Local Influence Approach , 2001, Biometrics.
[32] Kyle T. Bradley. Prognostic and Predictive Factors in Breast Cancer , 2007 .
[33] A. Giaccia,et al. The unique physiology of solid tumors: opportunities (and problems) for cancer therapy. , 1998, Cancer research.
[34] R. Porcher,et al. Evaluating treatment strategies in chronic lymphocytic leukemia: use of quality-adjusted survival analysis. , 2001, Journal of clinical epidemiology.
[35] S. Piantadosi,et al. Improved designs for dose escalation studies using pharmacokinetic measurements. , 1996, Statistics in medicine.
[36] D. Budman,et al. In vitro evaluation of synergism or antagonism with combinations of new cytotoxic agents. , 1998, Anti-cancer drugs.
[37] E. Raymond,et al. Phase I and pharmacokinetic study of the new vinca alkaloid vinflunine administered as a 10-min infusion every 3 weeks in patients with advanced solid tumours. , 2003, Annals of oncology : official journal of the European Society for Medical Oncology.
[38] Peter Nygren, Bengt Glimelius. The Swedish Council on Technology Assessment in Health Care (SBU) Report on Cancer Chemotherapy - Project Objectives, the Working Process, Key Definitions and General Aspects on Cancer Trial Methodology and Interpretation , 2001, Acta oncologica.
[39] S. Goodman,et al. Some practical improvements in the continual reassessment method for phase I studies. , 1995, Statistics in medicine.
[40] S. Venkatesh,et al. Role of the development scientist in compound lead selection and optimization. , 2000, Journal of pharmaceutical sciences.
[41] E J Freireich,et al. Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey, and man. , 1966, Cancer chemotherapy reports.
[42] G Molenberghs,et al. Evaluation of surrogate endpoints in randomized experiments with mixed discrete and continuous outcomes , 2001, Statistics in medicine.
[43] M. Wientjes,et al. Computational model of intracellular pharmacokinetics of paclitaxel. , 2000, The Journal of pharmacology and experimental therapeutics.
[44] A. Ahmed,et al. Cyclophosphamide (Cytoxan). A review on relevant pharmacology and clinical uses. , 1984, Journal of the American Academy of Dermatology.
[45] Animal models amd the molecular pathology of Cancer , 1997, The Journal of pathology.
[46] D. Toppmeyer. Phase I Trial Design and Methodology , 1997 .
[47] PETER ALEXANDER,et al. Cancer Chemotherapy , 1968, Nature.
[48] E. Gehan,et al. The determinatio of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent. , 1961, Journal of chronic diseases.
[49] P Nygren,et al. Assessment of quality of life during chemotherapy. , 2001, Acta oncologica.
[50] F. Mandelli,et al. Acute promyelocytic leukemia: clinical and morphologic features and prognostic factors. , 2001, Seminars in hematology.
[51] E K Rowinsky,et al. Ras protein farnesyltransferase: A strategic target for anticancer therapeutic development. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[52] E Wiltshaw,et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[53] Chang-Ho Ahn,et al. Regulatory considerations for preclinical development of anticancer drugs , 1997, Cancer Chemotherapy and Pharmacology.
[54] P. LoRusso,et al. In Vivo Methods for Screening and Preclinical Testing , 1997 .
[55] P F Thall,et al. A strategy for dose-finding and safety monitoring based on efficacy and adverse outcomes in phase I/II clinical trials. , 1998, Biometrics.
[56] Yuichi Sugiyama,et al. A Physiologically Based Pharmacokinetic Analysis of Capecitabine, a Triple Prodrug of 5-FU, in Humans: The Mechanism for Tumor-Selective Accumulation of 5-FU , 2001, Pharmaceutical Research.
[57] C. Veyrat‐Follet,et al. Clinical trial simulation of docetaxel in patients with cancer as a tool for dosage optimization , 2000, Clinical pharmacology and therapeutics.
[58] Explore Configuring,et al. A Simulation Study to , 2004 .
[59] R. Erb,et al. Introduction to Backpropagation Neural Network Computation , 1993, Pharmaceutical Research.
[60] M. Buyse,et al. What can we learn from a meta-analysis of trials testing the modulation of 5-FU by leucovorin? Advanced Colorectal Meta-analysis Project. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.
[61] Geert Molenberghs,et al. Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis , 2000, The Lancet.
[62] M. Ratain. Body-surface area as a basis for dosing of anticancer agents: science, myth, or habit? , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[63] H. Heimpel,et al. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group. , 1997, Journal of the National Cancer Institute.
[64] Geert Verbeke,et al. The Effect of Drop‐Out on the Efficiency of Longitudinal Experiments , 1999 .
[65] H. Ishitsuka,et al. Design of a novel oral fluoropyrimidine carbamate, capecitabine, which generates 5-fluorouracil selectively in tumours by enzymes concentrated in human liver and cancer tissue. , 1998, European journal of cancer.
[66] J. Mazoit,et al. Streptococcus pneumoniae pneumonia in mice: optimal amoxicillin dosing predicted from a pharmacokinetic-pharmacodynamic model. , 1999, The Journal of pharmacology and experimental therapeutics.
[67] J O'Quigley,et al. Continual reassessment method: a practical design for phase 1 clinical trials in cancer. , 1990, Biometrics.
[68] G. Rosen,et al. High-dose methotrexate with citrovorum factor rescue: predictive value of serum methotrexate concentrations and corrective measures to avert toxicity. , 1977, Cancer treatment reports.
[69] Daniel,et al. There are no bad anticancer agents, only bad clinical trial designs--twenty-first Richard and Hinda Rosenthal Foundation Award Lecture. , 1998 .
[70] G. Sledge,et al. Redefining the target: chemotherapeutics as antiangiogenics. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[71] R. Simon,et al. A model to select chemotherapy regimens for phase III trials for extensive-stage small-cell lung cancer. , 2000, Journal of the National Cancer Institute.
[72] Shawn C. D. Johnson,et al. The Role of Simulation in the Management of Research: What Can the Pharmaceutical Industry Learn from the Aerospace Industry? , 1998 .
[73] K. Goa,et al. Capecitabine: a review of its pharmacology and therapeutic efficacy in the management of advanced breast cancer. , 2003, Drugs.
[74] H. Gurney,et al. Dose calculation of anticancer drugs: a review of the current practice and introduction of an alternative. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[75] R Simon,et al. Clinical trial designs for cytostatic agents: are new approaches needed? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[76] HansâHelge Müller,et al. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches , 2001 .
[77] B. Druker,et al. Bcr-Abl inhibition as a modality of CML therapeutics. , 2001, Biochimica et biophysica acta.
[78] G. Hortobagyi. Overview of treatment results with trastuzumab (Herceptin) in metastatic breast cancer. , 2001, Seminars in oncology.
[79] James A. Powell,et al. Pharmacokinetics and Tolerability of an Antiangiogenic Ribozyme (ANGIOZYME™) in Healthy Volunteers , 2000, Journal of clinical pharmacology.
[80] G. Molenberghs,et al. The validation of surrogate endpoints in meta-analyses of randomized experiments. , 2000, Biostatistics.
[81] H. Schäfer,et al. Adaptive Group Sequential Designs for Clinical Trials: Combining the Advantages of Adaptive and of Classical Group Sequential Approaches , 2001, Biometrics.
[82] K. Blesch,et al. Population pharmacokinetics and concentration-effect relationships of capecitabine metabolites in colorectal cancer patients. , 2003, British journal of clinical pharmacology.
[83] R Henderson,et al. Joint modelling of longitudinal measurements and event time data. , 2000, Biostatistics.
[84] Y. Nakamura,et al. Genetic alterations during colorectal-tumor development. , 1988, The New England journal of medicine.
[85] L Aarons,et al. Role of modelling and simulation in Phase I drug development. , 2001, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.
[86] J L Steimer,et al. Exploring clinical study design by computer simulation based on pharmacokinetic/pharmacodynamic modelling. , 1997, International journal of clinical pharmacology and therapeutics.
[87] J. Bergh,et al. Lack of relationship between systemic exposure for the component drug of the fluorouracil, epirubicin, and 4-hydroxycyclophosphamide regimen in breast cancer patients. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[88] E Marubini,et al. Content and quality of currently published phase II cancer trials. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[89] R. Bruno,et al. Pharmacokinetic and pharmacodynamic properties of docetaxel: results of phase I and phase II trials. , 1997, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.
[90] K. Blesch,et al. Population Pharmacokinetic Analysis of the Major Metabolites of Capecitabine , 2002, Journal of Pharmacokinetics and Pharmacodynamics.
[91] Jeffrey R. Eisele,et al. A Curve‐Free Method for Phase I Clinical Trials , 2000, Biometrics.
[92] M Danhof,et al. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the effects of N6-cyclopentyladenosine analogs on heart rate in rat: estimation of in vivo operational affinity and efficacy at adenosine A1 receptors. , 1997, The Journal of pharmacology and experimental therapeutics.